NCT07327892 PENG Block vs PENG Plus Periarticular Injection vs Periarticular Injection in Older Adults
| NCT ID | NCT07327892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Poznan University of Medical Sciences |
| Condition | Hip Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2026-05-08 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2026-05-08 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pain after hip surgery is common in older adults and may limit early mobilization, increase the need for opioid medications, and contribute to complications such as delirium, nausea, or prolonged hospital stay. Effective postoperative pain management that preserves muscle strength and supports early rehabilitation is especially important in this population. Several analgesic strategies are currently used after hip surgery. Periarticular injection (PAI), administered by the surgeon during the procedure, is commonly used as part of standard care. The pericapsular nerve group (PENG) block is a newer ultrasound-guided regional anesthesia technique that targets the sensory nerves of the hip joint while sparing motor function. It may provide effective pain relief and facilitate early mobilization. However, it is unclear whether PENG block alone is superior to periarticular injection, and whether combining both techniques provides additional benefit. The aim of this randomized controlled clinical study is to compare three postoperative analgesic strategies in older adults undergoing hip surgery: PENG block alone, PENG block combined with periarticular injection, and periarticular injection alone. Participants will be randomly assigned to one of three study groups. The primary hypothesis is that regional anesthesia with a PENG block, either alone or combined with periarticular injection, will provide superior postoperative pain control compared with periarticular injection alone. A secondary hypothesis is that the combination of PENG block and periarticular injection will offer additional analgesic benefit compared with PENG block alone. Outcomes assessed in this study will include postoperative pain intensity, need for additional pain medications, time to first mobilization, and the occurrence of adverse events relevant to older adults, such as hypotension, excessive sedation, or postoperative delirium. The results of this study may help determine the most effective and practical analgesic strategy for hip surgery in older adults and support evidence-based optimization of postoperative pain management.
Eligibility Criteria
Inclusion Criteria: * Age 65 years or older * Scheduled for elective or emergency hip surgery (e.g., hip fracture fixation or hip arthroplasty) * ASA physical status I-III * Ability to communicate pain intensity using the NRS scale * Written informed consent obtained from the patient or legal representative Exclusion Criteria: * Patient refusal or inability to provide informed consent * Allergy, intolerance, or contraindication to any study medication: ropivacaine * Pre-existing neurological deficit or neuropathy of the affected limb * Coagulopathy (INR \>1.5, platelets \<100,000/µL) or current therapeutic anticoagulation that contraindicates regional anesthesia * Infection at or near the injection site * Severe hepatic or renal impairment * History of chronic opioid use (daily opioids \>30 days before surgery) * Cognitive impairment or delirium precluding reliable pain assessment * BMI \> 40 kg/m² (if you want to exclude for technical difficulty) * Patients receiving another regional nerve block for hip surgery * Pregnancy or breastfeeding * Participation in another interventional clinical trial within 30 days
Contact & Investigator
Malgorzata Reysner, MD PhD
STUDY CHAIR
Poznan University of Medical Sciences
Frequently Asked Questions
Who can join the NCT07327892 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 100 Years, studying Hip Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07327892 currently recruiting?
Yes, NCT07327892 is actively recruiting participants. Contact the research team at mreysner@ump.edu.pl for enrollment information.
Where is the NCT07327892 trial being conducted?
This trial is being conducted at Poznan, Poland.
Who is sponsoring the NCT07327892 clinical trial?
NCT07327892 is sponsored by Poznan University of Medical Sciences. The principal investigator is Malgorzata Reysner, MD PhD at Poznan University of Medical Sciences. The trial plans to enroll 108 participants.